201. PCD方案与VAD方案治疗多发性骨髓瘤的疗效及对血清VEGF、β2-MG水平的影响.
- Author
-
徐晓坤, 曾庆曙, 李婉, 马圣宇, and 杨云
- Subjects
- *
MULTIPLE myeloma , *VASCULAR endothelial growth factors , *BLOOD cells , *CYCLOPHOSPHAMIDE , *CONTROL groups - Abstract
Objective: To study the efficacy of epirubicin + vincristine + dexamethasone (VAD) and cyclophosphamide + bortezomib + dexamethasone (PCD) in the treatment of multiple myeloma and the effects on the serum levels of β2-MG and VEGF. Methods: Selected 40 cases of patients with multiple myeloma who were treated in our hospital from January 2017 to January 2020, divided into two groups randomly. The control group was treated with VAD regimen, and the observation group was treated with PCD regimen. The short-term efficacy, serum VEGF and β2-MG levels, and toxicity were compared between the two groups. Results: The effective rate of the observation group 50.00 % was significantly higher than that of the control group 20.00 %(P<0.05). After treatment, the serum VEGF and β2-MG levels of the two groups were significantly decreased, and the observation group were significantly lower than those of the control group (P<0.05). There was no significant difference in the total incidence of abdominal distension, blood cell deficiency or reduction and peripheral neurotoxicity between the two groups (P<0.05), and the incidence of blood cell deficiency or reduction in the observation group 5.00 % was significantly lower than that in the control group(P<0.05), and the incidence of peripheral neurotoxicity 30.00 % in the observation group was significantly higher than that in the control group (P<0.05). Conclusion: The short-term efficacy of PCD regimen is better than that of VAD regimen in patients with multiple myeloma, and can significantly improve the serum VEGF and β2-MG levels of patients. However, the dose should be controlled to prevent peripheral neurotoxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF